The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.
 
Daniel V.T. Catenacci
Honoraria - Amgen; Foundation Medicine; Genentech/Roche; Genmab; Guardant Health; Lilly; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Guardant Health; Lilly; NantWorks
Research Funding - Genentech; OncoPlex Diagnostics
 
Sunnie S. Kim
No Relationships to Disclose
 
Philip Jordan Gold
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merrimack; Novartis; Roche; Sanofi
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merrimack; novartis
Speakers' Bureau - amgen; Bayer; Celgene; roche; sanofi
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - Celgene; emd serono; Halozyme; Roche; sanofi
 
Peter C. Enzinger
Consulting or Advisory Role - Amgen; Five Prime Therapeutics; Merck; Pfizer; Sirtex Medical
 
Joe Coffie
Employment - Auxilium; Macrogenics; Mallinckrodt; MedImmune; MGI Pharma; PPD
Stock and Other Ownership Interests - Mallinckrodt
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Malcolm Baldwin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jeffrey L. Nordstrom
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
 
Ezio Bonvini
Employment - MacroGenics
Leadership - MacroGenics
Stock and Other Ownership Interests - Macrogenics
Research Funding - MacroGenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent application and issued patents held by the US Federal Government (I); Patent applications and issued patents held by MGNX
 
Jon M. Wigginton
Employment - Macrogenics
Leadership - Macrogenics
Stock and Other Ownership Interests - Macrogenics
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
 
Crystal Shereen Denlinger
Consulting or Advisory Role - Lilly; Merrimack
Research Funding - Astex Pharmaceuticals (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst); Pfizer (Inst)
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Research Funding - Advaxis; Bristol-Myers Squibb; Genentech/Roche; Macrogenics; Merrimack; Threshold Pharmaceuticals
 
Johanna C. Bendell
Research Funding - Apexigen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst)
 
Ronan Joseph Kelly
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Novartis
Research Funding - AstraZeneca (Inst)
 
Jan Kenneth Davidson-Moncada
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Patents, Royalties, Other Intellectual Property - National Cancer Institute
 
Albert C. Lockhart
Research Funding - Bayer (Inst); CTI (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Macrogenics (Inst); Millennium (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teva (Inst); Vertex (Inst); Zenyaku Kogyo (Inst)